Twist Bioscience stock extends rally with upside risk as overbought signals emerge

Traders Union
All News
Business & Wealth
Companies
Twist Bioscience stock jumps 10.4% today

Highlights

Twist Bioscience is advancing CAR-T therapy by integrating CRISPR and TALEN gene-editing to target diseases beyond cancer.
Shares jumped 10.3% to $101.06, giving Twist Bioscience a market capitalization near $5.83 billion on $409.4 million revenue.
Technical momentum remains bullish with a projected weekly trading range of $92.2 to $109.91, while resistance sits at $102.25.

The company's official account outlined how integrating CAR-T with CRISPR and TALEN technologies aims to enable more precise and scalable cell therapies for autoimmune, fibrotic, and genetic conditions. The post serves a promotional purpose, aiming to highlight Twist Bioscience’s capabilities within the diagnostics and research sector. Employment stands at 979 and the company has a market value near $5.83 billion, based on trailing revenue of $409.4 million.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish technical structure as price action leads past new information

The post supplied no new market driver, so recent price action unfolded independently of any fresh information. The stock's significant move was supported by technical dynamics: price action remains firmly above its MA-20, MA-50, and MA-200, keeping the daily structure bullish. With the nearest resistance at $102.25 and RSI at 62.4 approaching overbought territory, the advance is showing early signs of being stretched. These technical markers are currently guiding the market’s tone.

Upside potential stays firm as traders watch weekly high for confirmation

To gauge whether the recent advance has further room, traders should focus on the reaction to the weekly high at $102.25. The intraday range dramatically expanded, spanning from $82.44 up to $102.25, underlining the strength of the previous session. Over the coming trading week, the upside probability stands at 78% and downside at 22%, with an expected trading range of $92.2 to $109.91. A close above $102.25 would confirm buyers’ conviction, while a retreat below $93.93 would indicate the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.

Earlier, analysts noted that Twist Bioscience maintained a constructive technical outlook supported by bullish momentum and strong trend indicators. The current article builds on this perspective, with traders advised to monitor whether a sustained breakout above $102.25 can reinforce the upside scenario in the days ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.